IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$24.27 USD
-0.08 (-0.33%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $24.26 -0.01 (-0.04%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IDYA 24.27 -0.08(-0.33%)
Will IDYA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IDYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IDYA
Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss
IDYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates
All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know
Other News for IDYA
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | IDYA ...
IDEAYA Biosciences (IDYA) Price Target Raised by JP Morgan | IDYA Stock News
JPMorgan Raises Price Target for Ideaya Biosciences (IDYA) Amid Growth Potential
JPMorgan ups Ideaya target, adds to Analyst Focus List
IDEAYA Biosciences Announces Key Presentation at ESMO 2025 for Phase 2 Trial in Uveal Melanoma ...